HARVARD BIOSCIENCE Files 8-K for Reg FD Disclosure, Financials

TL;DR

**HBIO just filed an 8-K for a Reg FD disclosure, expect new financial info soon.**

AI Summary

HARVARD BIOSCIENCE, INC. filed an 8-K on January 5, 2024, to disclose that it is making a Regulation FD disclosure, which means it's sharing important, non-public information with the public to ensure fair access. This filing also covers results of operations and financial condition, and includes financial statements and exhibits. For investors, this matters because it signals that the company is proactively sharing information that could impact its stock price, and shareholders should pay close attention to the specific details of the financial condition and operational results that will be disclosed.

Why It Matters

This filing indicates HARVARD BIOSCIENCE is about to release significant financial or operational updates, which could directly influence investor sentiment and the stock's performance.

Risk Assessment

Risk Level: medium — The risk is medium because while the company is being transparent, the actual content of the financial and operational disclosures could be positive or negative, impacting the stock.

Analyst Insight

A smart investor would monitor HARVARD BIOSCIENCE, INC.'s subsequent announcements closely for the specific details of the financial condition and operational results mentioned in this 8-K, as these will drive the stock's immediate reaction.

Key Players & Entities

• HARVARD BIOSCIENCE, INC. (company) — the registrant filing the 8-K
• January 5, 2024 (date) — date of earliest event reported and filing date
• 001-33957 (other) — Commission File Number for HARVARD BIOSCIENCE, INC.
• HBIO (other) — Trading Symbol for Common Stock
• The NASDAQ Stock Market (other) — exchange where Common Stock is registered

Forward-Looking Statements

• HARVARD BIOSCIENCE, INC. will release specific financial results or operational updates shortly after this 8-K filing. (HARVARD BIOSCIENCE, INC.) — high confidence, target: 2024-01-12
• The stock price of HBIO will react to the specific details of the Regulation FD disclosure. (HBIO) — medium confidence, target: 2024-01-08

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value HBIO The NASDAQ Stock Marke

Filing Documents

• f8k_010524.htm (8-K) — 27KB
• exh_991.htm (EX-99.1) — 29KB
• exh991_01.jpg (GRAPHIC) — 60KB
• exh991_02.jpg (GRAPHIC) — 142KB
• exh991_03.jpg (GRAPHIC) — 93KB
• exh991_04.jpg (GRAPHIC) — 53KB
• exh991_05.jpg (GRAPHIC) — 53KB
• exh991_06.jpg (GRAPHIC) — 47KB
• exh991_07.jpg (GRAPHIC) — 69KB
• exh991_08.jpg (GRAPHIC) — 72KB
• exh991_09.jpg (GRAPHIC) — 42KB
• exh991_10.jpg (GRAPHIC) — 79KB
• exh991_11.jpg (GRAPHIC) — 78KB
• exh991_12.jpg (GRAPHIC) — 74KB
• exh991_13.jpg (GRAPHIC) — 59KB
• exh991_14.jpg (GRAPHIC) — 72KB
• exh991_15.jpg (GRAPHIC) — 51KB
• exh991_16.jpg (GRAPHIC) — 57KB
• exh991_17.jpg (GRAPHIC) — 7KB
• exh991_18.jpg (GRAPHIC) — 63KB
• 0001171843-24-000099.txt ( ) — 1843KB
• hbio-20240105.xsd (EX-101.SCH) — 3KB
• hbio-20240105_lab.xml (EX-101.LAB) — 33KB
• hbio-20240105_pre.xml (EX-101.PRE) — 22KB
• f8k_010524_htm.xml (XML) — 3KB

02. Results

Item 2.02. Results of Operations and Financial Condition Attached as Exhibit 99.1 is an investor presentation, dated January 5, 2024, that provides an overview of Harvard Bioscience, Inc. (the "Company"). The investor presentation includes, among other things, preliminary, unaudited estimates of the Company's full year 2023 revenue (the "Preliminary Financial Information"). The Preliminary Financial Information contained in the investor presentation is unaudited and preliminary and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2023 or its results of operations as of such date. This Preliminary Financial Information is subject to completion of the Company's normal financial close procedures. These procedures and the audit of the Company's financial The information in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished pursuant to Items 2.02 and 7.01 and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act. The information set forth in Items 2.02 and 7.01 shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

01. Regulation

Item 7.01. Regulation FD Disclosure The information contained in Item 2.02 is hereby incorporated into this Item 7.01 by reference.

01. Financial

Item 9.01. Financial (d) Exhibits. Exhibit No. Description 99.1 Harvard Bioscience, Inc. Investor Presentation 104 Cover Page Interactive Data File (embedded within the XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARVARD BIOSCIENCE, INC. Date: January 5, 2024 By: /s/ Jennifer Cote Jennifer Cote Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR